Cargando…

P1054: MYLOX-1: AN OPEN-LABEL, PHASE IIA STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR, GB2064, IN MYELOFIBROSIS

Detalles Bibliográficos
Autores principales:	Harrison, C., Mascarenhas, J., Rampal, R., Cilloni, D., Lindmark, B., Singh, B., Jacoby, B., Verstovsek, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429075/ http://dx.doi.org/10.1097/01.HS9.0000847084.19298.82

Ejemplares similares

P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

P1054: CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING
por: Garrote Ordeig, Marta, et al.
Publicado: (2023)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Biological drivers of clinical phenotype in myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2022)

2064: Deconstructing the peptide specificity of TCR recognition
por: Riley, Timothy P., et al.
Publicado: (2018)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Concerti pour clavecin BWV 1044, 1052, 1054
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1994)

Staphylococcus aureus 2064 growth as affected by temperature and reduced water activity
por: Medveďová, Alžbeta, et al.
Publicado: (2019)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
por: Kuykendall, Andrew, et al.
Publicado: (2023)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Single-incision laparoscopic transabdominal preperitoneal hernioplasty: 1,054 procedures and experience
por: Jiao, Jingyi, et al.
Publicado: (2023)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

2064 Regulation of retinal protein O-GlcNAcylation by angiotensin-(1-7) and cAMP
por: Dierschke, Sadie, et al.
Publicado: (2018)

2064. In Vitro Susceptibility of Recent Mycobacterium abscessus Isolates to Epetraborole (EBO) and Comparators by Broth Microdilution
por: Nguyen, Minh-Vu H, et al.
Publicado: (2023)

LOXL2 as a protective in osteoarthritis cartilage
por: Bais, Manish V., et al.
Publicado: (2017)

Identification and analysis of genomic islands in Burkholderia cenocepacia AU 1054 with emphasis on pathogenicity islands
por: Guo, Feng-Biao, et al.
Publicado: (2017)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2016)

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
por: Mughal, Tariq I, et al.
Publicado: (2014)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_16hgkv7mlcsffncb1ijg3cm875